Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendat false

קמהדע בע"מ	2 380
KAMADA LTD
Corporation no: 511524605	14096

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	17/05/2022
	www.isa.gov.il			www.tase.co.il				Reference:	2022-02-048510	Time of broadcast: 14:01 14:01

Immediate Report

Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on

Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue the Trial Without Modification

ea160092-6k_kamadaltdEDGAR1_Bannerless_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market: TASE	Date of revision of form structure: 27/04/2022
Address: Holtzman 2 4081 , Rehovot 7670402   ISRAEL , Tel: 08-9406472 , Fax: 08-9406473
E-mail address: liorf@kamada.com   Company site: www.kamada.com
Previous names of reporting entity:
Name of the Signatory: REFAEL MOSHE Position of Signatory in the reporting corporation: Company Controller Name of Employer Company:
Address: Holtzman 2 , Rehovot 7670402 Telephone: 08-9406472 Facsimile: 08-9406473 E-mail: mosheb@kamada.com 1